- March 15, 2022
- Newsletter
- 617-430-5616
Menu
Brand Name :
Firmagon
Synonyms :
degarelix
Class :
Antineoplastics and GnRH Antagonist
Dosage Forms & Strengths
Powder for injection
80mg
120mg
The initial dose was 240 mg as two subcutaneous injections of 120 mg each at a concentration of 40 mg per ml.
80 mg is given as the Maintenance Dose for one subcutaneous injection at a concentration of 20 mg per ml every 28 days
the first maintenance dose should be administered 28 days only after the initial dose
Dose Adjustments
Renal Dose Adjustments:
No adjustment is recommended for mild renal impairment (CrCl 50-80 ml per min)
Use with caution for moderate to severe renal impairment (CrCl <50 ml per min)
Liver Dose Adjustments:
No adjustment is recommended for mild to moderate Hepatic Impairment (Child-Pugh A and B)
Data not available and used with caution for Severe Hepatic Impairment (Child-Pugh C)
when both drugs are combined, there may be an increased risk or severity of QTC prolongation
when both drugs are combined, there may be an increased risk or severity of QTC prolongation
when both drugs are combined, there may be an increased risk or severity of QTC prolongation
when both drugs are combined, there may be an increased risk or severity of QTC prolongation
when both drugs are combined, there may be an increased risk or severity of QTC prolongation
it may enhance the qtc interval when combined with lofexidine
degarelix together with cisapride lead to an elevation of the QTc interval
QTc interval is increased both by lenvatinib and degarelix
when used together, entrectinib and degarelix both increase the QTc interval
when used together, encorafenib and degarelix both increase the QTc interval
It may enhance QTc interval when combined with pentamidine
when both drugs are combined, there may be an increased risk or severity of QTC prolongation
when both drugs are combined, there may be an increased risk or severity of QTC prolongation
when both drugs are combined, there may be an increased risk or severity of QTC prolongation
when both drugs are combined, there may be an increased risk or severity of QTC prolongation
when both drugs are combined, there may be an increased risk or severity of QTC prolongation
when both drugs are combined, there may be an increased risk or severity of QTC prolongation
when both drugs are combined, there may be an increased risk or severity of QTC prolongation
degarelix and loperamide are both known to elevate the QTc interval
when both drugs are combined, both increase the QTC interval
Adverse drug reaction
Frequency defined
>10%
Elevated liver enzymes
Hot flashes
Injection site erythema
Injection site pain
Weight gain
1-10%
Arthralgia
Back pain
Fatigue
HTN
Injection site induration or swelling
Pregnancy warnings:
Breastfeeding warnings:
Pregnancy Categories:
Patient Information Leaflet
Generic Name: degarelix (Rx)
Pronounced: DEH-guh-REH-lix
Why do we use degarelix?
degarelix is an anticancer drug used to treat advanced prostate cancers. This drug helps reduce the levels of testosterone hormone and prevents the spread of cancer cells.